|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500106473 |
|
最近更新日期: Date of Last Refreshed on: |
2025-07-24 10:24:11 |
|
注册时间: Date of Registration: |
2025-07-24 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
简化版加速康复外科管理方案对老年结直肠癌术后早期康复的影响 |
|
Public title: |
The impact of simplified accelerated rehabilitation surgical management plan on early postoperative recovery of elderly patients with colorectal cancer |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
简化版ERAS管理方案对老年结直肠癌术后早期康复的影响:一项多中心、非劣效性研究 |
|
Scientific title: |
The impact of simplified ERAS management plan on early postoperative rehabilitation of elderly patients with colorectal cancer: a multicenter, non inferiority study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈潮金 |
研究负责人: |
陈潮金 |
|
Applicant: |
Chaojin Chen |
Study leader: |
Chaojin Chen |
|
申请注册联系人电话: Applicant telephone: |
+86 134 3032 2182 |
研究负责人电话:
Study leader's |
+86 134 3032 2182 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
chenchj28@mail.sysu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
chenchj28@mail.sysu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广州市天河区天河路600号中山大学附属第三医院 |
研究负责人通讯地址: |
广州市天河区天河路600号 |
|
Applicant address: |
600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China |
Study leader's address: |
600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中山大学附属第三医院 |
||
|
Applicant's institution: |
Third Affiliated Hospital of Sun Yat sen University |
||
|
研究负责人所在单位: |
中山大学附属第三医院(中山大学肝脏病医院) |
||
|
Affiliation of the Leader: |
The Third Affiliated Hospital Sun Yat-sen University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
中大附三医伦II2025-025-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中山大学附属第三医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethic Committee of the Third Affiliated Hospital of Sun Yat-sen University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-02-14 00:00:00 | ||
|
伦理委员会联系人: |
黄凯琪 |
||
|
Contact Name of the ethic committee: |
Huang Kaiqi |
||
|
伦理委员会联系地址: |
广州市天河区天河路600号 |
||
|
Contact Address of the ethic committee: |
600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 8525 3302 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
420104114@qq.com |
|
研究实施负责(组长)单位: |
中山大学附属第三医院(中山大学肝脏病医院) |
||||||||||||||||||||||
|
Primary sponsor: |
The Third Affiliated Hospital Sun Yat-sen University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广州市天河区天河路600号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
江苏恩华药业股份有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Jiangsu Enhua Pharmaceutical Co., Ltd |
||||||||||||||||||||||
|
研究疾病: |
结直肠癌 |
||||||||||||||||||||||
|
Target disease: |
colorectal cancer |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
(1)术后早期康复指标上的非劣效性比较:比较标准ERAS管理组患者与简化版ERAS管理组患者术后住院并发症的发生率、术后睡眠情况、术后疼痛发生率、术后情绪变化和术后检验检查的优劣性; (2)评估简化版ERAS管理方案的经济优势:比较简化ERAS管理组患者对于标准ERAS管理组患者在住院时间、住院费用等方面的非劣效性; (3)评估简化版ERAS管理方案的可推广性:评估医生和护士对于简化ERAS管理措施和标准ERAS措施的执行率、接受度等;评估患者和家属对于两种ERAS管理措施的满意度和执行率;以此比较两种方案的可推广性。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) Non inferiority comparison of early postoperative rehabilitation indicators: Compare the incidence of postoperative hospitalization complications, postoperative sleep, postoperative pain, postoperative emotional changes, and the quality of postoperative examinations between patients in the standard ERAS management group and patients in the simplified ERAS management group; (2) Evaluate the economic advantages of the simplified ERAS management plan: Compare the non inferiority of the simplified ERAS management group patients to the standard ERAS management group patients in terms of hospitalization time, hospitalization costs, etc; (3) Evaluate the generalizability of the simplified ERAS management plan: assess the implementation rate, acceptance, etc. of doctors and nurses towards simplified ERAS management measures and standard ERAS measures; Evaluate the satisfaction and implementation rate of patients and their families towards the two ERAS management measures; Compare the generalizability of the two schemes based on this. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄:≥60岁; |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age >= 60 years old; 2. Patients planning to undergo radical surgery for colorectal cancer; |
||||||||||||||||||||||
|
排除标准: |
1.合并严重心肺功能不全; 2.肝肾功能衰竭; 3.凝血功能障碍。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Combined with severe cardiopulmonary dysfunction; 2. Liver and kidney failure; 3. Coagulation dysfunction. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-02-01 00:00:00至 To 2026-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-09-01 00:00:00 至 To 2026-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用分层区组随机化方法,按照中心分层,固定区组长度(区组长度为6)和随机数种子后,采用SAS软件产生随机数字表,并装入密封不透明的信封内,对于符合纳入排除标准的病例,每个中心按各自的区组顺序依次取用随机信封进行分组。(同一区组内的6个信封可随机取用,不需要按顺序)。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Using a stratified block randomization method, each center was stratified according to its own block order. After fixing the block length (block length of 6) and random number seeds, a random number table was generated using SAS software and placed in a sealed opaque envelope. For cases that met the inclusion and exclusion criteria, each center was divided into groups using random envelopes in their respective block order. Six envelopes within the same group can be randomly selected and do not need to be in order. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
单盲,对评估者设盲。 |
|
Blinding: |
Single blind study with blinded-evaluators |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
待研究成果发表后,原始数据在合理请求下与及经过双方医院伦理委员会批准可通过邮箱向研究负责人申请 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the research results are published, the original data can be applied to the research leader via email upon reasonable request and approval by the ethics committees of both hospitals. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集通过CRF表进行采集后,于电子记录文档中进行统一储存。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
After data collection through CRF forms, it is stored uniformly in electronic record documents. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |